Versartis Inc. (NASDAQ:VSAR)’s share price rose 3.7% during mid-day trading on Thursday . The company traded as high as $11.72 and last traded at $11.35, with a volume of 79,249 shares traded. The stock had previously closed at $10.95.

VSAR has been the topic of a number of recent analyst reports. Canaccord Genuity restated a “buy” rating on shares of Versartis in a report on Tuesday, May 10th. Zacks Investment Research lowered Versartis from a “hold” rating to a “sell” rating in a research report on Tuesday, May 17th. Northland Securities initiated coverage on Versartis in a research report on Thursday, April 7th. They set an “outperform” rating on the stock. Finally, Morgan Stanley reaffirmed a “hold” rating on shares of Versartis in a research report on Saturday, April 30th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $17.20.

The stock’s 50 day moving average price is $10.70 and its 200 day moving average price is $9.30. The stock’s market cap is $330.18 million.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.